日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction

模拟目标试验以评估心肌梗死后启动PCSK9抑制剂治疗时机有效性的方法学挑战

期刊:Pharmacoepidemiology and Drug Safety
影响因子:2.4
doi:10.1002/pds.70354
Cars, Thomas; Gustafsson, Stefan; Chan, Queenie; Dhalwani, Nafeesa; Kent, Shia T; Briggs, Andrew; Gale, Chris P; Gitt, Anselm; Jukema, J Wouter; Steg, Philippe Gabriel; Sundström, Johan; James, Stefan; Hagström, Emil; Brookhart, M Alan
CSK
心肌梗塞
PCSK9
心血管
发表日期：2026
文献求助 收藏

Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry

在患有动脉粥样硬化性心血管疾病和 2 型糖尿病的极高危患者中，达到基于指南的血脂目标的情况：来自 cvMOBIUS2 注册研究的 213,380 名受试者的结果

期刊:American Journal of Preventive Cardiology
影响因子:5.9
doi:10.1016/j.ajpc.2024.100921
Shoji, Satoshi; Shah, Nishant P; Shrader, Peter; Thomas, Laine E; Arnold, Jonathan D; Dhalwani, Nafeesa N; Thomas, Neena A; Kalich, Bethany; Priest, Elisa L; Syed, Mahanaz; Wójcik, Cezary; Peterson, Eric D; Navar, Ann Marie
心血管疾病
心血管
代谢
糖尿病
动脉粥样硬化
发表日期：2025
文献求助 收藏

Characterisation of a clinical trial-like population of high cardiovascular risk patients prior to myocardial infarction or stroke in the real world: design and protocol for a multidatabase retrospective cohort study

在真实世界中，对类似临床试验的高心血管风险患者人群（发生心肌梗死或卒中前）进行特征分析：一项多数据库回顾性队列研究的设计和方案

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-092702
Ochs, Andreas; Chan, Queenie; Dhalwani, Nafeesa N; Duxbury, Michael; Shannon, Erin; O'Kelly, James; Paiva da Silva Lima, Gabriel; Avcil, Suna; Chan, Adrienne Yl; Chui, Celine Sl; Lai, Edward Chia-Cheng; Cars, Thomas; Shin, Ju-Young Judy; Heintjes, Edith M; Wong, Ian Ck
心肌梗塞
心血管
发表日期：2025
文献求助 收藏

Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study

利用阴性对照结果比较心肌梗死后PCSK9单克隆抗体治疗策略：一项Target试验模拟研究

期刊:Epidemiology
影响因子:4.4
doi:10.1097/EDE.0000000000001730
Sloot, Rosa; Breskin, Alexander; Colantonio, Lisandro D; Allmon, Andrew G; Yu, Ying; Sakhuja, Swati; Chen, Ligong; Muntner, Paul; Brookhart, M Alan; Dhalwani, Nafeesa
PCSK9
心血管
心肌梗塞
CSK
单克隆抗体
发表日期：2024
文献求助 收藏

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

德国临床实践中基于依洛尤单抗的低密度脂蛋白胆固醇管理在高危和极高危心血管风险患者中的应用：HEYMANS 研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02757-x
Lehrke, Michael; Vogt, Anja; Schettler, Volker; Girndt, Matthias; Fraass, Uwe; Tabbert-Zitzler, Anja; Bridges, Ian; Dhalwani, Nafeesa N; Ray, Kausik K
代谢
发表日期：2024
文献求助 收藏

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings

在真实世界环境中，PCSK9抑制剂单克隆抗体与依折麦布的持续性和依从性比较

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02868-z
Muntner, Paul; Ghazi, Lama; Jones, Jenna; Dhalwani, Nafeesa; Poudel, Bharat; Wen, Ying; Chen, Ligong; Wang, Zhixin; Bittner, Vera; Kalich, Bethany; Farkouh, Michael E; Woodward, Mark; Colantonio, Lisandro D; Rosenson, Robert S
单克隆抗体
CSK
PCSK9
发表日期：2024
文献求助 收藏

Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study

依洛尤单抗在瑞士临床实践中的应用：HEYMANS观察性队列研究的最终数据

期刊:Therapeutic Advances in Cardiovascular Disease
影响因子:2.2
doi:10.1177/17539447231213288
Sudano, Isabella; Krähenbühl, Stephan; Mach, François; Anstett, Anne; Dhalwani, Nafeesa; Bridges, Ian; Sibartie, Mahendra; Ray, Kausik K
发表日期：2024
文献求助 收藏

Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries

医疗保险受益人在心肌梗死住院后进行低密度脂蛋白胆固醇检测

期刊:JACC Advances
影响因子:
doi:10.1016/j.jacadv.2023.100753
Colantonio, Lisandro D; Wang, Zhixin; Jones, Jenna; Dhalwani, Nafeesa N; Shannon, Erin D; Liu, Cici; Kalich, Bethany A; Muntner, Paul; Rosenson, Robert S; Bittner, Vera
心肌梗塞
心血管
代谢
发表日期：2024
文献求助 收藏

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study

在中欧和东欧，依洛尤单抗治疗的起始低密度脂蛋白胆固醇（LDL-C）水平远高于指南推荐水平：来自 HEYMANS 观察性研究的结果

期刊:
影响因子:
doi:10.15420/ecr.2023.18.PO19
Blaha, V; Margoczy, R; Petrov, I; Postadzhiyan, A; Raslova, K; Rosolova, H; Bridges, I; Dhalwani, N N; Zachlederova, M; Ray, K K
代谢
发表日期：2023
文献求助 收藏

Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

低密度脂蛋白胆固醇水平超过欧洲推荐的PCSK9抑制剂起始治疗阈值：来自HEYMANS研究的启示

期刊:European Heart Journal-Quality of Care and Clinical Outcomes
影响因子:4.6
doi:10.1093/ehjqcco/qcac009
Ray, Kausik K; Dhalwani, Nafeesa; Sibartie, Mahendra; Bridges, Ian; Ebenbichler, Christoph; Perrone-Filardi, Pasquale; Villa, Guillermo; Vogt, Anja; Bruckert, Eric
CSK
PCSK9
代谢
发表日期：2022
文献求助 收藏